Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • ADVERTISEMENT FEATURE Advertiser retains sole responsibility for the content of this article

Spider venom shows potential as treatment for epilepsy, stroke and pain

The University of Queensland’s Professor Glenn King is the first to admit his fascination with venom came by chance. A collaborator asked him to analyze a toxin found in the venom of Australia’s deadly funnel-web spider. The work led to clues about the toxin’s function, a paper in Nature Structural and Molecular Biology, and eventually a change in King’s research focus from cancer to venom.

King would eventually discover that funnel-web venom has more than 3,000 components, making it “probably the most complex chemical arsenal in the natural world”.

The research has already yielded an insecticide derived from funnel-web spider venom that is now marketed in the US by Vestaron Corporation, a spin-off company King founded while working at the University of Connecticut.

His work has not stopped with bug spray; King’s lab at The University of Queensland contains the most extensive collection of venoms in the world, with samples from more than 600 species of spiders, scorpions, centipedes, and assassin bugs.

© The University of Queensland

Like other venomous animals investigated by his team, funnel-web spider venom contains small proteins or peptides that interact with, and modulate the activity of, ion channels and receptors in mammalian neurons.

That discovery led King and his team to focus on ion channels involved in human disorders such as epilepsy, pain, and stroke. “We know these venoms are full of ion channel modulators, so we thought maybe we could use them as libraries to screen against ion channel drug targets that we know about,” he says.

The approach has had phenomenal success, with King’s laboratory uncovering possible therapies for Dravet syndrome, epilepsy, abdominal pain, and stroke.

Dravet syndrome is a rare and life-threatening form of epilepsy that strikes children in the first year of life. It is caused by a mutation that reduces the amount of NaV1.1, a key sodium channel in the brain that is critical for regulating brain excitability.

Working in collaboration with Steven Petrou at the Florey Institute of Neuroscience and Mental Health, King’s team found a peptide in funnel-web spider venom that restores normal function of this channel and eliminates seizures.

“We started giving Dravet syndrome mice the spider-venom peptide after they developed serious seizures, and within four days we had eliminated all the seizures and the mice were saved from premature death,” King says. “That is really exciting, but the issue now is how to best deliver that drug to the brain, and that is a technical issue that needs to be solved before moving into clinical trials.”

Funnel-web spider venom has also proven to be the key ingredient in his work on strokes. During a stroke, acid-sensing ion channel 1a is activated and this sets off a death spiral for neurons. King’s team has found a funnel-web spider venom peptide that binds to this channel and stops it from becoming activated during stroke.

With two million neurons dying every minute without treatment, time is of the essence during a stroke.

However, as King points out, there are two kinds of stroke. “We have only one drug available for ischemic stroke, but it can make things worse for haemorrhagic stroke, so you can’t give the drug until you get the patient to hospital and image the brain.

© The University of Queensland

“The drug we are developing should be fine for both types of stroke, which means patients could be given the drug straight away and their brain would be protected.”

The discovery’s potential is global, as stroke kills six million people worldwide each year, and leaves five million survivors with a permanent disability. “We are pretty excited about it, but it is also a difficult challenge because we still need to find the best way to get the drug into the brain.”

Meanwhile, his work on gut pain does not require the drug to pass the blood-brain barrier and is closer to clinical trials. “We stumbled across a spider-venom peptide that activated neurons through a different sodium channel that no one thought was involved in pain,” he says. “It turns out this channel is important for the abdominal pain associated with irritable bowel syndrome.”

“We have now found a venom peptide that inhibits this channel and does a great job of stopping the gut pain associated with IBS.”

King does not have a favourite source of venom, but he does have a soft spot for the Australian funnel-web spider, which has repeatedly shown potential as a supplier of eco-friendly insecticides and human therapeutics. Australian wildlife’s venomous reputation may one day prove to be an unexpected lifesaver.

For more information on the University of Queensland research, please visit:

Related Articles


Quick links